SVRA · Insider Trading
Savara Inc.
Every open-market purchase and sale reported by SVRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Braden C. Parker | Chief Commercial Officer | F | −29,323 | −$148.67K |
| 2026-07-24 | Robert Matthew Lutz | Chief Fin. & Operating Officer | A | +35,000 | — |
| 2026-06-22 | David L Lowrance | Chief Financial Officer | MIXED | — | −$2.24M |
| 2026-03-20 | David L Lowrance | Chief Financial Officer | MIXED | +249,987 | −$16 |
| 2026-02-17 | Joseph S McCracken | Director | M | +1,807 | +$3.18K |
| 2025-12-19 | David A Ramsay | Director | Sell | −20,000 | −$121.22K |
| 2025-12-16 | David L Lowrance | Chief Financial Officer | MIXED | −94,960 | −$435.68K |
| 2025-12-16 | Kathleen R. McCabe | Chief Legal Officer | F | −39,350 | −$272.30K |
| 2025-12-16 | Robert Matthew Lutz | Chief Operating Officer | F | −67,760 | −$468.90K |
| 2025-12-16 | Anne Erickson | Chief Business Officer | F | −62,960 | −$435.68K |
| 2025-12-16 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | −324,700 | −$1.35M |
| 2025-12-11 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | G | −23,629 | — |
| 2025-12-11 | An van Es-Johansson | Director | A | +40,000 | — |
| 2025-12-11 | Richard J Hawkins | Director | A | +40,000 | — |
| 2025-12-11 | Joseph S McCracken | Director | A | +40,000 | — |
| 2025-12-11 | Nevan C Elam | Director | A | +40,000 | — |
| 2025-12-11 | David A Ramsay | Director | A | +40,000 | — |
| 2025-12-04 | Yasmine Wasfi | Chief Medical Officer | F | −21,992 | −$140.09K |
| 2025-12-04 | Nevan C Elam | Director | MIXED | +4,387 | −$3 |
| 2025-11-17 | Richard J Hawkins | Director | M | +5,860 | +$8.56K |
| 2025-10-22 | Yasmine Wasfi | Chief Medical Officer | A | +35,000 | — |
| 2025-06-23 | Richard J Hawkins | Director | Buy | +48,225 | +$98.57K |
| 2025-06-02 | Joseph S McCracken | Director | Buy | +10,000 | +$20.82K |
| 2025-04-01 | David A Ramsay | Director | Buy | +150,000 | +$416.25K |
| 2025-02-14 | Robert Matthew Lutz | Chief Operating Officer | F | −38,263 | −$108.28K |
| 2024-12-16 | David A Ramsay | Director | A | +40,000 | — |
| 2024-12-16 | Nevan C Elam | Director | A | +40,000 | — |
| 2024-12-16 | An van Es-Johansson | Director | A | +40,000 | — |
| 2024-12-16 | David L Lowrance | Chief Financial Officer | MIXED | +38,650 | −$161.44K |
| 2024-12-16 | Richard J Hawkins | Director | MIXED | +32,000 | −$26.57K |
| 2024-12-16 | Braden C. Parker | Chief Commercial Officer | A | +20,000 | — |
| 2024-12-16 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | +252,705 | −$478.05K |
| 2024-12-16 | Raymond Dennis Pratt | Chief Medical Officer | A | +80,000 | — |
| 2024-12-16 | Joseph S McCracken | Director | A | +40,000 | — |
| 2024-12-16 | Anne Erickson | Chief Business Officer | MIXED | +81,737 | −$58.62K |
| 2024-12-16 | Robert Matthew Lutz | Chief Operating Officer | A | +100,000 | — |
| 2024-11-20 | Joseph S McCracken | Director | Buy | +20,000 | +$59.07K |
| 2024-11-18 | David A Ramsay | Director | Buy | +100,000 | +$287.60K |
| 2024-11-12 | Raymond Dennis Pratt | Chief Medical Officer | F | −49,950 | −$198.30K |
| 2024-10-22 | Anne Erickson | Chief Business Officer | F | −381 | −$1.36K |
| 2024-09-27 | Braden C. Parker | Chief Commercial Officer | A | +85,000 | — |
| 2024-07-22 | Anne Erickson | Chief Business Officer | F | −381 | −$1.70K |
| 2024-04-23 | Anne Erickson | Chief Business Officer | F | −381 | −$1.83K |
| 2023-12-29 | David L Lowrance | CHIEF FINANCIAL OFFICER | Sell | −10,000 | −$47.13K |
| 2023-12-29 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | −103,000 | −$395.90K |
| 2023-12-29 | Nevan C Elam | Director | MIXED | −40,085 | −$372.57K |
| 2023-12-18 | Raymond Dennis Pratt | Chief Medical Officer | A | +150,000 | — |
| 2023-12-15 | Joseph S McCracken | Director | A | +22,500 | — |
| 2023-12-15 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | +340,320 | −$488.08K |
| 2023-12-15 | Nevan C Elam | Director | A | +22,500 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David A Ramsay | Director | 2,533,642 | $12.24M |
| Matthew Pauls | CHIEF EXECUTIVE OFFICER | 1,188,050 | $5.74M |
| David L Lowrance | Chief Financial Officer | 896,297 | $4.33M |
| Kathleen R. McCabe | Chief Legal Officer | 519,232 | $2.51M |
| Anne Erickson | Chief Business Officer | 371,712 | $1.80M |
| Raymond Dennis Pratt | Chief Medical Officer | 340,050 | $1.64M |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 328,977 | $1.59M |
| Joseph S McCracken | Director | 302,644 | $1.46M |
| Yasmine Wasfi | Chief Medical Officer | 168,008 | $811.48K |
| Richard J Hawkins | Director | 161,326 | $779.20K |
| Nevan C Elam | Director | 106,887 | $516.26K |
| An van Es-Johansson | Director | 102,500 | $495.07K |
| Braden C. Parker | Chief Commercial Officer | 75,677 | $365.52K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SVRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.